



SINGAPORE O&G LTD.

(Company Registration Number 201100687M)

FOR IMMEDIATE RELEASE

Singapore O&G Ltd. Achieves 16.6% Growth In 1H 2015 Group Revenue

- **1H 2015 Net profit up 6.8% over the same period last year**
- **Net operating margin remains healthy at 35.1%.**
- **Declares an interim and first tax exempt dividend post IPO of 0.88 Singapore cents per share.**

Singapore, 6 August 2015 – Singapore O&G Ltd. (“**SOG**” or the “**Group**”), a SGX Catalist listed company specialising in women’s healthcare, announced today its financial results for the half year ended 30 June 2015 (“1H 2015”). The Group’s net profit after tax attributable to shareholders increased by S\$0.2 million or 6.8%, and revenue increased by S\$1.1 million or 16.6%, over the same period last year.

The Group’s core business of Obstetrics and General Gynaecology continues to perform solidly with a total delivery of 749 babies in 1H 2015. The Group delivered 1,462 babies for the full year of 2014. SOG Women Cancer Specialists, Dr. Cindy Pang and Dr. Radhika Lakshmanan, are establishing themselves, seeing increased number of patients and contributed meaningfully to our profits .

The Group continues to have good control over its consumables and medical supplies used with a marginal improvement in gross profit margin of approximately 1.0%. Excluding one-off items which were the remaining IPO expenses of S\$0.3 million, and additional government grants received in 1H 2015 of S\$0.1 million, the Group’s net profit after tax would have been S\$2.9 million, an improvement of S\$0.4 million or 14.3% over the corresponding period. The Group anticipates its net operating margin to be stable for the second half of the year.

As at 30 June 2015, the Group’s balance sheet remains healthy with net cash generated from operating activities of S\$2.7 million, cash and cash equivalents amounted to S\$22.4 million, and no borrowings and debt securities.



SINGAPORE O&G LTD.

(Company Registration Number 201100687M)

The Board of Directors of SOG is pleased to declare an interim dividend of 0.88 Singapore cents per share. In the Company's Initial Public Offer, the Company noted that it intends to distribute up to 90.0% of our net profit after tax to our Shareholders for the financial year ended 31 December 2015, as we wish to reward our Shareholders for participating in our Group's growth. The Board of Directors is thus pleased to declare the maiden interim dividend of 0.88 Singapore cents per share. Barring any unforeseen circumstances, the final dividend should be larger than the interim dividend in FY 2015.

Dr. Ng Koon Keng, CEO of SOG said: "Demand for good antenatal and gynaecological treatments remain strong. SOG is benefiting from the Singapore Government's initiative to increase birth rate. Besides such growth, SOG is also seeking to increase market share by offering more value added packages aimed at both local residents and medical tourists.

Regretfully the rising incidence of cancer continues to plague both men and women in Singapore. With the establishment of SOG Women Cancer Specialists, I believe, SOG is well positioned to provide affordable and effective treatment for both breast and gynaecological cancers.

The Company remains positive about FY 2015 and barring any unforeseen circumstances, the Group will continue to be profitable for the second half of the year".

- END -



SINGAPORE O&G LTD.

(Company Registration Number 201100687M)

ABOUT SINGAPORE O&G LTD. (“SOG” or the “Group”)

SOG comprises specialist medical practitioners in women’s healthcare with a long and established track record in the Obstetrics and Gynaecology (“O&G”) field. SOG’s particular focus is on pregnancy care and delivery, the female reproductive system, and gynaecological and breast cancer. SOG’s business is best described as the provision of O&G services, which includes general and ancillary surgical services. Since December 2014, SOG has also started offering breast and gynaecological cancer treatments, and general surgical services.

The Group is led by its Chairman, Dr. Lee Keen Whye, its CEO, Dr. Ng Koon Keng and its Executive Directors, Dr Heng Tung Lan and Dr. Beh Suan Tiong. In particular, both Dr. Lee Keen Whye and Dr. Heng Tung Lan have more than 20 years’ experience in the O&G field. Additionally, Dr. Ng Koon Keng has business development, management, marketing and publishing experience and spearheads the marketing and business development activities of the Group.

For more information, please visit SOG’s website at www.sog.com.sg.

This press release has been prepared by the Group and its contents have been reviewed by Hong Leong Finance Limited (the “Sponsor”) for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (“SGX-ST”). The Sponsor has not independently verified the contents of this press release. This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made, or reports contained in this press release. The contact person for the Sponsor is Ms Joan Ling, Senior Vice President, Head of Corporate Finance, at 16 Raffles Quay, #40-01A Hong Leong Building, Singapore 048581, Telephone (65) 6415 9886.